Oteseconazole - Generic Drug Details

What are the generic drug sources for oteseconazole and what is the scope of freedom to operate?

Oteseconazole is the generic ingredient in one branded drug marketed by Mycovia Pharms and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Oteseconazole has sixty-four patent family members in twenty-two countries.

One supplier is listed for this compound.

Summary for oteseconazole

International Patents:	64
US Patents:	5
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	25
Patent Applications:	115
What excipients (inactive ingredients) are in oteseconazole?	oteseconazole excipients list
DailyMed Link:	oteseconazole at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for oteseconazole

Constraining patent/regulatory exclusivity:

10,414,751

Dosage:

CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for oteseconazole

Drug Class	Azole Antifungal
Mechanism of Action	Breast Cancer Resistance Protein Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for oteseconazole

J02AC	Triazole and tetrazole derivatives
J02A	ANTIMYCOTICS FOR SYSTEMIC USE
J02	ANTIMYCOTICS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

US Patents and Regulatory Information for oteseconazole

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mycovia Pharms	VIVJOA	oteseconazole	CAPSULE;ORAL	215888-001	Apr 26, 2022		RX	Yes	Yes
Mycovia Pharms	VIVJOA	oteseconazole	CAPSULE;ORAL	215888-001	Apr 26, 2022		RX	Yes	Yes	8,236,962		Y	Y
Mycovia Pharms	VIVJOA	oteseconazole	CAPSULE;ORAL	215888-001	Apr 26, 2022		RX	Yes	Yes	8,754,227
Mycovia Pharms	VIVJOA	oteseconazole	CAPSULE;ORAL	215888-001	Apr 26, 2022		RX	Yes	Yes	10,414,751		Y	Y
Mycovia Pharms	VIVJOA	oteseconazole	CAPSULE;ORAL	215888-001	Apr 26, 2022		RX	Yes	Yes

International Patents for oteseconazole

Country	Patent Number	Title	Estimated Expiration
Brazil	112014017751
Taiwan	I578987
World Intellectual Property Organization (WIPO)	2016149486
Portugal	2563771
Brazil	112012027308

Market Dynamics and Financial Trajectory for Oteseconazole

Last updated: February 19, 2026

What Is Oteseconazole?

Oteseconazole is an oral antifungal agent developed by Mycovia Pharmaceuticals. It belongs to the azole class, targeting fungal infections, including recurrent vulvovaginal candidiasis (RVVC). The drug's mechanism inhibits fungal CYP51 (lanosterol demethylase), disrupting ergosterol synthesis vital for fungal cell membrane integrity.

Current Development and Approval Status

• Phase: Oteseconazole is in late-stage clinical trials, with pivotal Phase 3 data released in 2022.
• Regulatory progress: Mycovia submitted New Drug Application (NDA) to the FDA in September 2022, with review ongoing.
• Indications: Focused on recurrent RVVC, with potential expansion to other fungal infections.

Market Size and Demand Drivers

Parameter	Data	Source
Global vulvovaginal candidiasis market	$620 million (2021)	Grand View Research[1]
Recurrent RVVC cases globally	138 million annually	WHO[2]
Estimated RVVC treatment market share for novel agents	20% by 2027	Market Research Future[3]

Growth factors influencing demand include rising antifungal resistance, limitations of existing azole therapies, and patient preference for oral, once-daily treatments.

Competitive Landscape

Competitors	Key Products	Market Position	Approximate Market Share (2022)
Fluconazole (Pfizer)	Diflucan	Market leader	50%+
Itraconazole (Janssen)	Sporanox	Secondary player	20-25%
Oteseconazole (Mycovia)	Oteseconazole	Awaiting approval	0% (pending)

Mycovia aims to capture market share through improved efficacy against resistant strains, safety profile, and reduced recurrence rates.

Key Differentiators and Potential Advantages

• Spectrum: Broad activity, including strains resistant to fluconazole.
• Dosing: Oral, daily, with favorable pharmacokinetics.
• Efficacy: Phase 2/3 data demonstrates superior recurrence prevention compared to fluconazole.
• Safety: Minimal drug-drug interactions; well tolerated in trials.

Financial Trajectory and Revenue Potential

Assumptions

• Approval achieved in 2024.
• Initial launch in the U.S. and Europe.
• Competitive pricing aligned with existing azoles (~$50-$100 per treatment course).
• First-year sales projections based on market penetration of 5-10%, scaling to 20% by year 5.

Revenue Estimates

Year	Market Penetration	Estimated Sales	Notes
2024	5%	$31 million	Limited due to regulatory review
2025	10%	$62 million	Post-approval ramp-up
2026	15%	$93 million	Expansion into additional markets
2027	20%	$124 million	Peak of initial launch phase

Cost and Profitability Considerations

• R&D: Estimated total outlay of $150 million pre-approval.
• Manufacturing: Scaled supply chain expected to reduce per-unit costs.
• Pricing: Competitive with existing azoles; margin potential of 50-60% post-commercialization.

Regulatory and Commercial Risks

• Delays in NDA review or rejection.
• Competition from off-patent generics reducing pricing power.
• Unanticipated adverse events affecting safety profile.
• Market acceptance slower than projected due to physician or patient preferences.

Key Market Trends Affecting Oteseconazole

• Rise in antifungal resistance, creating demand for new agents.
• Shift towards oral, outpatient treatments.
• Increasing prevalence of RVVC worldwide.
• Regulatory incentives for novel antibiotics/antifungals in certain jurisdictions.

Regulatory and IP Considerations

• Mycovia's patent estate covers formulations and specific use cases, expiring around 2035.
• Orphan drug designation pending in the U.S., potentially offering seven-year exclusivity.

Summary of Investment and R&D Outlook

• Oteseconazole has projected peak sales in the hundreds of millions of dollars.
• It faces a competitive landscape but benefits from its profile against resistant strains.
• Successful approval and market access could accelerate revenue growth.
• Continued R&D could expand indications into invasive fungal infections.

---

Key Takeaways

• Oteseconazole targets a high-need fungal infection market with significant growth prospects.
• It faces competition from established azoles but offers advantages in resistance management.
• Revenue potential depends heavily on regulatory approval timing and market acceptance.
• Early-stage commercialization could generate revenues over $100 million annually within five years.
• Strategic patent and IP protections are crucial for maintaining market exclusivity.

---

FAQs

1. When is Oteseconazole expected to launch commercially?
Regulatory review ongoing; approval anticipated in late 2023 or early 2024, with commercialization in 2024.

2. What are the primary clinical advantages of Oteseconazole over existing therapies?
Higher efficacy in preventing recurrent infections and activity against resistant fungal strains, with favorable safety and dosing profiles.

3. How large is the market opportunity for Oteseconazole?
The global RVVC treatment market is valued at approximately $620 million, with potential growth to over $1 billion, driven by rising prevalence and resistance.

4. What competitive threats does Oteseconazole face?
Off-patent azoles and emerging antifungals, pricing pressures, and any adverse regulatory developments.

5. What are the key challenges for Oteseconazole’s commercial success?
Regulatory approval, market acceptance, competition, and healthcare provider familiarity with new agents.

---

References

[1] Grand View Research. (2022). Vaginal Candidiasis Market Size, Share & Trends Analysis.
[2] World Health Organization. (2020). Global prevalence of fungal infections.
[3] Market Research Future. (2022). Antifungal Drugs Market Research Report.